New research article
Novel #dengue serotype 4 live virus human challenge: a phase 1 dose optimisation and homologous rechallenge study
www.thelancet.com/journals/lan...
#IDSky #ClinMicro #MicroSky #ViroSky #OpenAccess #OA
Novel #dengue serotype 4 live virus human challenge: a phase 1 dose optimisation and homologous rechallenge study
www.thelancet.com/journals/lan...
#IDSky #ClinMicro #MicroSky #ViroSky #OpenAccess #OA
October 29, 2026 at 1:46 PM
New research article
Novel #dengue serotype 4 live virus human challenge: a phase 1 dose optimisation and homologous rechallenge study
www.thelancet.com/journals/lan...
#IDSky #ClinMicro #MicroSky #ViroSky #OpenAccess #OA
Novel #dengue serotype 4 live virus human challenge: a phase 1 dose optimisation and homologous rechallenge study
www.thelancet.com/journals/lan...
#IDSky #ClinMicro #MicroSky #ViroSky #OpenAccess #OA
3/3 Novel dengue serotype 4 live virus human challenge: a phase 1 dose optimisation and homologous rechallenge study.
Lancet Microbe · 29 Oct 2026
doi.org/10.1016/j.lanmic.2026.101542
Lancet Microbe · 29 Oct 2026
doi.org/10.1016/j.lanmic.2026.101542
November 4, 2026 at 4:13 PM
3/3 Novel dengue serotype 4 live virus human challenge: a phase 1 dose optimisation and homologous rechallenge study.
Lancet Microbe · 29 Oct 2026
doi.org/10.1016/j.lanmic.2026.101542
Lancet Microbe · 29 Oct 2026
doi.org/10.1016/j.lanmic.2026.101542
#ESMO26: Preliminary data support encorafenib and cetuximab #rechallenge in metastatic colorectal cancer (#mCRC), although questions remain around patient selection and treatment specifications, as discussed by Rona Yaeger
🔗 https://ow.ly/6bmH5100p2M
#InsightsbyESMO
🔗 https://ow.ly/6bmH5100p2M
#InsightsbyESMO
October 29, 2026 at 2:10 PM
#ESMO26: Preliminary data support encorafenib and cetuximab #rechallenge in metastatic colorectal cancer (#mCRC), although questions remain around patient selection and treatment specifications, as discussed by Rona Yaeger
🔗 https://ow.ly/6bmH5100p2M
#InsightsbyESMO
🔗 https://ow.ly/6bmH5100p2M
#InsightsbyESMO
Nerandomilast-Associated Pneumonitis With a Positive Rechallenge: A Case Report
onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com/doi/10.1002/...
https://onlinelibrary.wiley.com/doi/10.1002/rcr2.70786
onlinelibrary.wiley.com
October 26, 2026 at 2:00 AM
Nerandomilast-Associated Pneumonitis With a Positive Rechallenge: A Case Report
onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com/doi/10.1002/...
Sublethal whole body irradiation impairs the kinetics, subset composition, and function of memory CD4 T cells, compromising their ability to mount effective recall responses to clear the infection, affecting patients with a history of radiation exposure. https://ow.ly/rHA250ZZ1VW.
October 21, 2026 at 4:30 PM
Sublethal whole body irradiation impairs the kinetics, subset composition, and function of memory CD4 T cells, compromising their ability to mount effective recall responses to clear the infection, affecting patients with a history of radiation exposure. https://ow.ly/rHA250ZZ1VW.
Letter to editor
Behavioral tics following sublingual allergen immunotherapy (OSIRIS): A case report
#Allergenic #Immunotherapy #Sublingual #Allergen-specific-immunotherapy #Tic-disorders #Rechallenge
www.em-consulte.com/article/1846...
Behavioral tics following sublingual allergen immunotherapy (OSIRIS): A case report
#Allergenic #Immunotherapy #Sublingual #Allergen-specific-immunotherapy #Tic-disorders #Rechallenge
www.em-consulte.com/article/1846...
Behavioral tics following sublingual allergen immunotherapy (OSIRIS): A case report
Behavioral tics following sublingual allergen immunotherapy (OSIRIS): A case report
www.em-consulte.com
October 16, 2026 at 6:54 AM
Letter to editor
Behavioral tics following sublingual allergen immunotherapy (OSIRIS): A case report
#Allergenic #Immunotherapy #Sublingual #Allergen-specific-immunotherapy #Tic-disorders #Rechallenge
www.em-consulte.com/article/1846...
Behavioral tics following sublingual allergen immunotherapy (OSIRIS): A case report
#Allergenic #Immunotherapy #Sublingual #Allergen-specific-immunotherapy #Tic-disorders #Rechallenge
www.em-consulte.com/article/1846...
Rechallenge the flying gym, dude pulls out Dragonite, Aerodactyl, Salamence, Vespiqueen, Drifblim, Yanmega, and dares you to call it unfair
October 14, 2026 at 3:38 PM
Rechallenge the flying gym, dude pulls out Dragonite, Aerodactyl, Salamence, Vespiqueen, Drifblim, Yanmega, and dares you to call it unfair
I do enjoy the concept in later games/certain fanhacks that they clearly have a team tuned for an appropriate beginner challenge, and when you rechallenge them they pull out all the stops to trip up their normal hard counters, like TM moves and strange/rare 'mon choices.
October 14, 2026 at 3:35 PM
I do enjoy the concept in later games/certain fanhacks that they clearly have a team tuned for an appropriate beginner challenge, and when you rechallenge them they pull out all the stops to trip up their normal hard counters, like TM moves and strange/rare 'mon choices.
The Legend of Zelda: Ocarina of Time remake features a new Hall of Fallen Foes enemy gallery
The Legend of Zelda: Ocarina of Time remake features a new Hall of Fallen Foes enemy gallery
The Hall of Fallen Foes allows players to examine defeated enemies and rechallenge boss fights.
dlvr.it
October 14, 2026 at 2:24 PM
The Legend of Zelda: Ocarina of Time remake features a new Hall of Fallen Foes enemy gallery
WO2026205975A1 - a TROP2-targeted IFNβ fusion designed to bypass ADC resistance and stimulate antitumour immunity. ABN202 induced complete responses; 3/5 responders resisted tumour rechallenge, suggesting durable immune memory. Tumour selectivity and normal-tissue toxicity remain key questions.
October 10, 2026 at 9:03 AM
WO2026205975A1 - a TROP2-targeted IFNβ fusion designed to bypass ADC resistance and stimulate antitumour immunity. ABN202 induced complete responses; 3/5 responders resisted tumour rechallenge, suggesting durable immune memory. Tumour selectivity and normal-tissue toxicity remain key questions.
Hear me out -
Should I rechallenge the 100 Character Drawing, but only in doodle-fy style headshot like this for this week's Art-Thursday?
If interested, drop your PNG and imma draw as many as I can
Should I rechallenge the 100 Character Drawing, but only in doodle-fy style headshot like this for this week's Art-Thursday?
If interested, drop your PNG and imma draw as many as I can
October 7, 2026 at 2:45 AM
Hear me out -
Should I rechallenge the 100 Character Drawing, but only in doodle-fy style headshot like this for this week's Art-Thursday?
If interested, drop your PNG and imma draw as many as I can
Should I rechallenge the 100 Character Drawing, but only in doodle-fy style headshot like this for this week's Art-Thursday?
If interested, drop your PNG and imma draw as many as I can
If I beat ch 3 I can rechallenge him?
October 6, 2026 at 1:35 AM
If I beat ch 3 I can rechallenge him?
📢 New Review in #LiversMDPI
🧬 Vemula et al. review second- and third-line strategies after ICI failure in HCC.
🩺 TKIs remain the most widely used second-line option, while evidence for ICI rechallenge remains limited.
📖 Read More: www.mdpi.com/2673-4389/6/...
#HCC #TKIs
🧬 Vemula et al. review second- and third-line strategies after ICI failure in HCC.
🩺 TKIs remain the most widely used second-line option, while evidence for ICI rechallenge remains limited.
📖 Read More: www.mdpi.com/2673-4389/6/...
#HCC #TKIs
October 5, 2026 at 11:10 AM
📢 New Review in #LiversMDPI
🧬 Vemula et al. review second- and third-line strategies after ICI failure in HCC.
🩺 TKIs remain the most widely used second-line option, while evidence for ICI rechallenge remains limited.
📖 Read More: www.mdpi.com/2673-4389/6/...
#HCC #TKIs
🧬 Vemula et al. review second- and third-line strategies after ICI failure in HCC.
🩺 TKIs remain the most widely used second-line option, while evidence for ICI rechallenge remains limited.
📖 Read More: www.mdpi.com/2673-4389/6/...
#HCC #TKIs
Bruh you can't downplay that run, it definitely counts.
And yeah they told me I have to rechallenge if I want to claim reigning Champ as like, a position... When I won the first time they told I was too young and I needed to come back older. Bunch of bs, honestly! I'm gonna do it undefeated
And yeah they told me I have to rechallenge if I want to claim reigning Champ as like, a position... When I won the first time they told I was too young and I needed to come back older. Bunch of bs, honestly! I'm gonna do it undefeated
October 1, 2026 at 1:02 AM
Bruh you can't downplay that run, it definitely counts.
And yeah they told me I have to rechallenge if I want to claim reigning Champ as like, a position... When I won the first time they told I was too young and I needed to come back older. Bunch of bs, honestly! I'm gonna do it undefeated
And yeah they told me I have to rechallenge if I want to claim reigning Champ as like, a position... When I won the first time they told I was too young and I needed to come back older. Bunch of bs, honestly! I'm gonna do it undefeated
I went to go claim my Champion job now that I'm not 15 and they told me I had to rechallenge?? Very unclear if they meant the whole League or what, so I guess I'm on New Game Plus.
September 29, 2026 at 4:51 AM
I went to go claim my Champion job now that I'm not 15 and they told me I had to rechallenge?? Very unclear if they meant the whole League or what, so I guess I'm on New Game Plus.
also the Dancer Resonant was SOOOOOOOOOOO much fun omg I hope there's a way to rechallenge these bosses
September 27, 2026 at 2:47 PM
also the Dancer Resonant was SOOOOOOOOOOO much fun omg I hope there's a way to rechallenge these bosses
Ophthopedia Update: Combined Infliximab and Tofacitinib Therapy for Severe Refractory Juvenile Idiopathic Arthritis Associated Panuveitis: A Challenge, Dechallenge, Rechallenge Case Report: .
Combined Infliximab and Tofacitinib Therapy for Severe Refractory Juvenile Idiopathic Arthritis Associated Panuveitis: A Challenge, Dechallenge, Rechallenge Case Report
.
dlvr.it
September 27, 2026 at 10:21 AM
Ophthopedia Update: Combined Infliximab and Tofacitinib Therapy for Severe Refractory Juvenile Idiopathic Arthritis Associated Panuveitis: A Challenge, Dechallenge, Rechallenge Case Report: .
🚨 DAY 2 | #GUARDSymposium2026 Coverage by OncoAlert
After progression, what's the right next line—TKI, IO rechallenge, or a HIF-2a combination? The evidence isn't equal across options. 🧭
At #GUARDSymposium2026, Dr. Javier Molina 🇪🇸, Servicio de Oncología Médica, Hospital Universitario Ramón y Cajal
After progression, what's the right next line—TKI, IO rechallenge, or a HIF-2a combination? The evidence isn't equal across options. 🧭
At #GUARDSymposium2026, Dr. Javier Molina 🇪🇸, Servicio de Oncología Médica, Hospital Universitario Ramón y Cajal
September 17, 2026 at 1:45 PM
🚨 DAY 2 | #GUARDSymposium2026 Coverage by OncoAlert
After progression, what's the right next line—TKI, IO rechallenge, or a HIF-2a combination? The evidence isn't equal across options. 🧭
At #GUARDSymposium2026, Dr. Javier Molina 🇪🇸, Servicio de Oncología Médica, Hospital Universitario Ramón y Cajal
After progression, what's the right next line—TKI, IO rechallenge, or a HIF-2a combination? The evidence isn't equal across options. 🧭
At #GUARDSymposium2026, Dr. Javier Molina 🇪🇸, Servicio de Oncología Médica, Hospital Universitario Ramón y Cajal
Neuropenia (low neutrophils, a type of white blood cell) can be caused by rituximab as a treatment of multiple sclerosis even many years after taking the medication (image shows neutrophil count vs. days since onset of neutropenia) . pubmed.ncbi.nlm.nih.gov/42743451/
Late-Onset Neutropenia After Rituximab in Multiple Sclerosis: Incidence, Predictors, and Outcomes in a Retrospective Multicenter Cohort - PubMed
In this large real-world cohort, high-grade LON (grades 3-4) events were rare and frequently complicated by infections. Mild (grade 2) LON events were often fluctuating and generally clinically uneventful. Rechallenge with rituximab was rarely complicated by serious adverse events. Prediction of LON …
pubmed.ncbi.nlm.nih.gov
September 16, 2026 at 9:08 PM
Neuropenia (low neutrophils, a type of white blood cell) can be caused by rituximab as a treatment of multiple sclerosis even many years after taking the medication (image shows neutrophil count vs. days since onset of neutropenia) . pubmed.ncbi.nlm.nih.gov/42743451/
Treatment Strategies for Biomarker-Negative and PI3K-Pathway Altered HR+/HER2− mBC | CancerNetwork
Explore evolving options for biomarker-negative metastatic breast cancer, from CDK4/6 rechallenge to gadeptolizumab and PAM-pathway targeted therapy.
www.cancernetwork.com
September 16, 2026 at 10:07 AM
September 15, 2026 at 6:27 PM
the guy goes "hah!! I beat you!! I'm going to run away and not let you rechallenge me so I can keep my win over you!!" and that's his final appearance in the entire series
September 15, 2026 at 2:25 AM
the guy goes "hah!! I beat you!! I'm going to run away and not let you rechallenge me so I can keep my win over you!!" and that's his final appearance in the entire series
University of Cambridge, groups of 4 to 11 mice. Gut-activated CD4+ T cells traveled via CXCR6-CXCL16 to the brain’s borders, formed months-long antigen memory and rapidly recalled it on rechallenge.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Intestinal infections establish antigen-specific, long-lived memory CD4+ T cells in the brain and meninges - Nature Neuroscience
Intestinal CD4+ T cells migrate to the dura and brain following gut infection with bacteria or parasites, establishing a long-lived memory population capable of proliferation and cytokine production f...
www.nature.com
September 8, 2026 at 6:01 PM
University of Cambridge, groups of 4 to 11 mice. Gut-activated CD4+ T cells traveled via CXCR6-CXCL16 to the brain’s borders, formed months-long antigen memory and rapidly recalled it on rechallenge.
www.nature.com/articles/s41...
www.nature.com/articles/s41...